Many thanks for all of your input this week. We covered the case of a 68 year old lady presenting with macrocytic anaemia and thrombocytosis. Key points in initial investigation:
Exclude common causes – iron deficiency, B12/folate deficiency, myeloma screen, reactive causes, medications, myeloproliferative disorder (JAK2, CAL-R, MPL, BCR-ABL)
Her film showed evidence of dysplasia and so we organised a BM aspirate which confirmed dysplasia in two cell lineages. Cytogenetics confirmed our diagnosis of MDS with isolated del(5q)
Key recommendations regarding MDS del(5q)
Supportive care as per all patients with MDS:
Blood product support – although need to note that prognosis tends to be better (median survival at least 6 years) and so consider alternative strategies or iron chelation if indicated
Judicious treatment of infection
First-line to consider a trial of erythrocyte stimulating agent (ESA) e.g. EPO. Trial for 8 weeks, and then increase dose if no response for a further 8 weeks. Trial should last no longer than 16 weeks.
Patients who are transfusion-dependent or unsuitable/non-responders to ESA can be considered for lenalidomide – usually 10mg OD for 21 days in a 28 day cycle. Consider thromboprophylaxis on an individual basis
Further information is accessible on the BSH guideline:
Please reply to us (@TeamHaem) on Twitter and always include #TeamHaem to allow others to follow your comments. Please join in the debate and learn about haematological problems along the way. The case will continue to evolve over the coming week so keep checking #TeamHaem on Twitter for more information.
Please note – all cases on TeamHaem are entirely fictional to protect patient confidentiality.
TeamHaem are not a position of authority. It is an educational platform to allow discussion and learning.